Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 16/20 | 0.76 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL92287 | 0.85 | SMN1; SMN2 (0.65) | HIF1ASMN1; SMN2 | |
| SCHEMBL92201 | 0.83 | HIF1A (0.58) | HIF1AMAPTSMN1; SMN2 | |
| SCHEMBL92286 | 0.83 | HIF1A (0.73) | HIF1ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL92212 | 0.83 | HIF1A (0.68) | HIF1AMAPT | |
| SCHEMBL91601 | 0.78 | KDM4E (0.54) | HIF1AEPHX1MAPTKDM4EMEN1 | |
| SCHEMBL91537 | 0.78 | MAPT (0.64) | EPHX1MAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL92544 | 0.77 | MAPT (0.58) | MAPTSMN1; SMN2LMNA | |
| SCHEMBL91568 | 0.77 | EPHX1 (0.49) | EPHX1MAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL3468374 | 0.76 | HIF1A (0.71) | HIF1AMAPTSMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL92200 | 0.75 | HIF1A (0.70) | HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130065882-A1 | VLA-4 inhibitory drug | MACHINAGA NOBUO (JP) | 2013-03-14 | — | — | US | disclosed |
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-06-21 | — | — | US | disclosed |
| US-8129366-B2 | VLA-4 inhibitory drug | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | HIF1A 652/4885EPHX1 2783/4885MAPT 4775/4885 |
| US-20130065882-A1 | VLA-4 inhibitory drug | VCAM1, ITGB4, ITGA4 | HIF1A 594/4885EPHX1 2558/4885MAPT 4773/4885 |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | HIF1A 980/4885EPHX1 3733/4885MAPT 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.